Table 3.

Analyses of lipid profile, body fat composition, and CRP.

Secondary outcomes (lipid profile, body fat composition, and CRP)	Period	Group				P*	(P inter)
		Placebo group (N = 55)		TJ001 group (N = 57)
		Mean ± S.D.	(P intra)	Mean ± S.D.	(P intra)
Lipid profile
Cholesterol
Total cholesterol, mg/dL	Baseline	207.3 ± 36.8	0.1142	191.7 ± 31.5	0.0983	0.0180	0.8980
	week 12	201.9 ± 39.6		187.2 ± 34.3		0.0374
HDL cholesterol, mg/dL	Baseline	46.9 ± 9.90	0.8695	46.1 ± 10.6	0.7240	0.7161	0.2717
	week 12	47.2 ± 10.9		45.9 ± 9.70		0.5249
Triglyceride, g/dL	Baseline	152.2 ± 87.2	0.4709	134.6 ± 66.9	0.8306	0.2352	0.4977
	week 12	143.3 ± 87.9		133.3 ± 64.5		0.4963
Body fat composition
Total fat area (TFA), cm2	Baseline	402.8 ± 153.9	0.2103	392.5 ± 134.6	0.1201	0.7105	0.5205
	week 12	387.9 ± 134.2		383.4 ± 137.0		0.8601
Visceral fat area (VFA), cm2	Baseline	118.2 ± 58.1	0.4255	110.1 ± 47.0	0.2669	0.4252	0.6621
	week 12	115.9 ± 58.5		105.4 ± 51.8		0.3253
Subcutaneous fat area (SFA), cm2	Baseline	283.6 ± 116.3	0.2898	282.1 ± 103.0	0.2582	0.9425	0.3767
	week 12	272.1 ± 102.1		278.2 ± 105.2		0.7579
VFA/SFA	Baseline	0.44 ± 0.21	0.3921	0.40 ± 0.17	0.5682	0.2524	0.8109
	week 12	0.43 ± 0.21		0.39 ± 0.19		0.3055
C-reactive protein (CRP), mg/dL	Baseline	0.83 ± 0.17	0.3766	0.78 ± 0.18	0.6834	0.1547	0.3731
	week 12	0.85 ± 0.19		0.79 ± 0.19		0.0721

P*: A P value for between-group comparison at each visit and visit X group interaction using ANOVA.

(P _intra): A P value for within-group comparison between baseline and 5th visit by paired t-test.

(P _inter): A P value for between-group comparison after 12-week treatment using ANCOVA (baseline as covariate).

P < 0.05 were considered statistically significant.